DE60324406D1 - Modifizierter faktor viii - Google Patents

Modifizierter faktor viii

Info

Publication number
DE60324406D1
DE60324406D1 DE60324406T DE60324406T DE60324406D1 DE 60324406 D1 DE60324406 D1 DE 60324406D1 DE 60324406 T DE60324406 T DE 60324406T DE 60324406 T DE60324406 T DE 60324406T DE 60324406 D1 DE60324406 D1 DE 60324406D1
Authority
DE
Germany
Prior art keywords
factor viii
fviii
modified
modified factor
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324406T
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Francis J Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of DE60324406D1 publication Critical patent/DE60324406D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60324406T 2002-04-18 2003-04-17 Modifizierter faktor viii Expired - Fee Related DE60324406D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02008712 2002-04-18
EP03006554 2003-03-24
PCT/EP2003/004063 WO2003087161A1 (en) 2002-04-18 2003-04-17 Modified factor viii

Publications (1)

Publication Number Publication Date
DE60324406D1 true DE60324406D1 (de) 2008-12-11

Family

ID=29252205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324406T Expired - Fee Related DE60324406D1 (de) 2002-04-18 2003-04-17 Modifizierter faktor viii

Country Status (15)

Country Link
US (1) US20050256304A1 (de)
EP (1) EP1495052B9 (de)
JP (1) JP2005538694A (de)
KR (1) KR20040103970A (de)
CN (1) CN1646564A (de)
AT (1) ATE412671T1 (de)
AU (1) AU2003232482A1 (de)
BR (1) BR0308860A (de)
CA (1) CA2482926A1 (de)
DE (1) DE60324406D1 (de)
ES (1) ES2319758T3 (de)
MX (1) MXPA04010061A (de)
PL (1) PL371278A1 (de)
RU (1) RU2004133761A (de)
WO (1) WO2003087161A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1636360A4 (de) 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
PL1824988T3 (pl) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2008157776A2 (en) * 2007-06-21 2008-12-24 Angelica Therapeutics, Inc. Modified diphtheria toxins
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2780761A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
EP2524054A2 (de) * 2010-01-14 2012-11-21 Haplomics, Inc. Vorhersage und reduktion der alloimmunogenität von proteintherapeutika
SG10201600656WA (en) * 2010-10-27 2016-02-26 Baxter Int FVIII Peptides For Immune Tolerance Induction And Immunodiagnostics
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
BR112015023793A2 (pt) * 2013-03-15 2017-07-18 Us Dept Veterans Affairs composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a
CA2906602A1 (en) * 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
WO2019197524A1 (en) * 2018-04-12 2019-10-17 Biotest Ag De-immunized factor viii molecule and pharmaceutical compositions comprising the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US20020068303A1 (en) * 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
AU6486196A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
CA2290485C (en) * 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
ES2278463T3 (es) * 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Also Published As

Publication number Publication date
EP1495052A1 (de) 2005-01-12
CA2482926A1 (en) 2003-10-23
KR20040103970A (ko) 2004-12-09
JP2005538694A (ja) 2005-12-22
WO2003087161A1 (en) 2003-10-23
CN1646564A (zh) 2005-07-27
MXPA04010061A (es) 2004-12-13
PL371278A1 (en) 2005-06-13
RU2004133761A (ru) 2005-07-10
BR0308860A (pt) 2005-01-04
AU2003232482A1 (en) 2003-10-27
EP1495052B9 (de) 2009-12-16
ATE412671T1 (de) 2008-11-15
EP1495052B1 (de) 2008-10-29
US20050256304A1 (en) 2005-11-17
ES2319758T3 (es) 2009-05-12

Similar Documents

Publication Publication Date Title
ATE412671T1 (de) Modifizierter faktor viii
MXPA04001982A (es) Factor ix modificado.
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
EP3533461A3 (de) Von prame abstammende peptide und immunogene zusammensetzungen damit
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HK1101131A1 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
ATE319745T1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
EP1373301A4 (de) Abschwächung der immunogenizität von fusionsproteinen
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
HUP0400700A2 (hu) Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF)
EA201070681A1 (ru) Пептиды fviii и их применение для индукции толерантности у больных гемофилией
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
DE60322225D1 (en) T-zellen-epitope in erythropoietin
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
MXPA04001976A (es) Hormona de crecimiento humano modificada.
HUP0303430A2 (hu) Csökkentett immunogenitású, módosított protamin
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
HUP0401121A2 (hu) Csökkentett immunogenitású, módosított trombopoietin (TPO)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee